High SGK1 levels were found in suicide victims and people with genetic risk after childhood trauma. Blocking SGK1 may offer a new antidepressant option for treatment-resistant patients.
- SGK1 levels were elevated in people with childhood trauma and depression
- SGK1 appears to biologically link early adversity to suicide risk
- Blocking SGK1 may lead to trauma-specific antidepressants
Why do some people who had difficult childhoods struggle with depression or
Scientists at Columbia University and McGill University believe they have found one biological clue: a stress-related brain chemical called SGK1 (1✔ ✔Trusted Source
Hippocampal SGK1 promotes vulnerability to depression: the role of early life adversity, stress, and genetic risk
Go to source
).
In a new study published in Molecular Psychiatry, researchers showed that SGK1 levels are significantly higher in people who faced early-life adversity and later died by suicide. They also found that children who carry genetic variants that boost SGK1 production were more likely to develop depression as teenagers.
This suggests that SGK1 may act as a molecular bridge between childhood trauma and later mental-health vulnerability.
TOP INSIGHT
Early trauma can leave biological traces — and one brain protein may help explain why. #mentalhealth #medindia #childhoodtrauma #suicideprevention #sgk1
Inside the Study: How SGK1 Connects Trauma to Mood Disorders
The team examined brain tissue from adults who died by suicide. Among those with a history of childhood trauma, SGK1 levels were up to twice as high as in those without early hardship.
They also studied genetic data from young people who experienced adversity. Children with SGK1-increasing variants were more likely to develop depression during adolescence.
Earlier work by the same team had already identified elevated SGK1 in the blood of unmedicated adults with depression.
Together, these results suggest a clear pattern:
Childhood Trauma
↓
Increased SGK1 Levels
↓
Altered Stress & Mood Pathways
↓
Higher Risk of Depression
↓
Higher Risk of Suicidal Thoughts/Behavior
Why SGK1 Matters
SGK1 is a protein involved in the body’s stress response. When activated repeatedly — as happens in chronic adversity — it can alter how the brain processes emotion, regulates mood, and responds to future stressors.
Importantly, current antidepressants like SSRIs often work less effectively for people with trauma histories. This study hints at why: their biology may follow a different pathway, one that SGK1 directly influences.
Lead author Dr. Christoph Anacker explains: “Current antidepressants don’t work as well for people with early-life adversity. SGK1 gives us a biological target that may help us design better treatments.“
A New Kind of Antidepressant?
One of the study’s most promising findings comes from animal experiments. When mice were given SGK1-blocking drugs, they did not develop depressive-like behaviors even under chronic stress. Since SGK1 inhibitors already exist for other medical conditions, researchers believe clinical trials could begin relatively soon.
Potential future uses include:
- SGK1-targeted antidepressants for trauma-affected patients
- Genetic screening to identify individuals at highest risk
- Precision treatment plans based on a patient’s stress biology
This could represent one of the first trauma-specific antidepressant strategies.
The Bigger Picture: Why Trauma Changes Biology
Childhood trauma is one of the strongest predictors of adult depression. But not all trauma survivors develop mental illness, meaning biology plays a crucial role.
SGK1 may be one of the key switches that stays turned on long after the adversity ends, influencing how the brain reacts to stress years later.
Understanding this pathway could help:
- identify high-risk individuals earlier
- offer targeted therapy rather than one-size-fits-all antidepressants
- guide suicide-prevention strategies in vulnerable populations
Final Takeaway
This study doesn’t mean trauma seals someone’s fate, but it reveals a powerful biological link that could transform how depression is treated.
SGK1 may be one of the missing pieces connecting early hardship to lifelong emotional vulnerability. And blocking it might one day offer hope to the millions of people whose depression doesn’t respond to standard treatments.
Reference:
- Hippocampal SGK1 promotes vulnerability to depression: the role of early life adversity, stress, and genetic risk – (https://www.nature.com/articles/s41380-025-03269-6)
Source-Medindia